Valuation : Myriad Genetics, Inc.

Market Cap 304M 262M 246M 224M 423M 29.07B 424M 2.92B 1.14B 14.67B 1.14B 1.12B 48.66B P/E 2026 *
-2x
P/E 2027 * -2.6x
Enterprise Value 304M 262M 246M 224M 423M 29.07B 424M 2.92B 1.14B 14.67B 1.14B 1.12B 48.66B EV / Sales 2026 *
0.39x
EV / Sales 2027 * 0.37x
Free-Float
96.03%
Yield 2026 *
-
Yield 2027 * -
1 day-0.31%
1 week-0.94%
Current month+10.84%
1 month-40.41%
3 months-24.88%
6 months-36.73%
Current year-48.46%
1 week 3
Extreme 3
3.27
1 month 2.74
Extreme 2.74
5.43
Current year 2.74
Extreme 2.74
7.15
1 year 2.74
Extreme 2.74
8.59
3 years 2.74
Extreme 2.74
29.3
5 years 2.74
Extreme 2.74
36.95
10 years 2.74
Extreme 2.74
50.44
Manager TitleAgeSince
Chief Executive Officer 54 2025-04-29
Director of Finance/CFO 43 2025-08-15
Chief Tech/Sci/R&D Officer - 2026-05-31
Director TitleAgeSince
Chairman 67 2020-03-22
Director/Board Member 71 2010-06-09
Director/Board Member 66 2019-09-24
Date Insider Type Main position Quantity % Market Cap.
8/16/26 Tax

Chief Financial Officer

-8,761 0.0093%
6/11/26 Free

Chief Executive Officer

3,542 0.0038%
6/4/26 Free

Director

59,701 0.0632%
Change 5-day change 1-year change 3-year change Capi.($)
-1.10%-0.94%-49.04%-81.96% 304M
-4.15%-5.71%+149.65%+321.11% 22.61B
-0.33%+0.87%-36.76%-21.34% 10.35B
-5.07%-5.44%+331.23%+30.36% 8.45B
-2.77%-2.72%-33.15% - 7.45B
+0.27%+0.78%+81.53%+51.73% 6.56B
+2.72%-4.42%-12.56%-9.48% 5.94B
-0.49%+2.54%-10.05%-17.63% 4.44B
-2.23%-2.58%+69.78%+105.33% 4.33B
-1.34%-5.24%-19.36%-27.00% 2.85B
Average -1.44%+1.17%+47.13%+39.01% 7.33B
Weighted average by Cap. -2.30%+1.45%+84.64%+119.34%

Financials

2026 *2027 *
Net sales 778M 670M 628M 574M 1.08B 74.32B 1.08B 7.45B 2.91B 37.52B 2.92B 2.86B 124B 822M 708M 664M 606M 1.14B 78.54B 1.15B 7.88B 3.07B 39.65B 3.09B 3.02B 131B
Net income -143M -124M -116M -106M -199M -13.7B -200M -1.37B -536M -6.91B -538M -526M -22.93B -104M -89.45M -83.86M -76.56M -144M -9.92B -145M -995M -388M -5.01B -390M -381M -16.61B
Net Debt - -
Logo Myriad Genetics, Inc.
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Employees
2,700
Date Price Change Volume
26-08-28 $3.160 -0.63% 1,429,693
26-08-27 $3.180 +1.92% 1,278,031
26-08-26 $3.120 -2.19% 1,288,004
26-08-25 $3.190 +4.59% 1,757,379
26-08-24 $3.050 -4.69% 1,352,465
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
3.180USD
Average target price
3.769USD
Spread / Average Target
+18.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MYGN Stock